Method of treating a disease condition susceptible to baclofen therapy

Abstract

The present invention discloses a method of treating a disease condition susceptible to baclofen therapy, said method comprising orally administering once-a-day in the evening a controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivatives and pharmaceutically acceptable excipients.

Description

FIELD OF INVENTION[0001]The present invention relates to an effective method of treating a disease condition susceptible to baclofen therapy, said method comprising administering a controlled release drug delivery system of baclofen or its pharmaceutically acceptable salts or its derivatives.[0002]The present invention also relates to an effective method of treating disease conditions susceptible to baclofen therapy, said method comprising administering a controlled release drug delivery system of baclofen or its pharmaceutically acceptable salts or its derivatives and to the use of baclofen for such treatment.BACKGROUND OF THE INVENTION[0003]U.S. Pat. No. 3,471,548 disclosed 4-amino-3-(p-chlorophenyl)butyric acid). 4-amino-3-(p-chlorophenyl)butyric acid) designates the R-isomers, the S-isomer and mixtures of R and S isomers including the racemate. Baclofen is indicated in many disease conditions such as for alleviating signs and symptoms of spasticity resulting from multiple sclero...

AI Technical Summary

Benefits of technology

[0017]It has surprisingly been found that when controlled release drug delivery system comprising baclofen or its pharmaceutically acceptable salt or its derivative was administered to human subjects in the evening in the fed state, the maximum plasma concentration of baclofen (Cmax) achieved after administration of the system in evening was sustained over a longer duration (see FIG. 1 and FIG. 3) than compared to that after administration of the system in the morning in the fed state. Surprisingly when the system was administered in the evening, it was observed that the duration over which absorption of baclofen occurred was prolonged and higher plasma levels were maintained during the latter half of the dosing period as compared to those obtained by morning dosing. Evening dosing thus can provide an optimum maintenance of relief from the systems of the disease condition by maintaining baclofen levels at higher therapeutic effective plasma concentrations even in the latter half of the dosing period.

Problems solved by technology

Frequent administration of immediate release baclofen tablets leads to fluctuations in plasma concentration producing peaks and troughs.

Peaks in plasma concentration are associated with side effects, such as drowsiness (sedation), dizziness and muscle weakness and troughs cause inadequate control of muscle spasm.

Although a single daily administration of the full daily dose (referred to as “high dose” to signify the higher amount of baclofen in a single sustained release tablet compared to that in one immediate release tablet even though the total daily dose remains the same) would be convenient however, the problem was that when baclofen was given in single high daily doses as sustained or controlled release preparation the bioavailability was reduced.

Anything in the stomach is expected to be cleared due to these strong contractions or otherwise cause the problems of blocking of the pyloric sphincter or accumulation of the object in the stomach after it is repeatedly ingested by the human subject.

It is also not possible to use a dosage form that would resist such housekeeper waves because it will be totally unacceptable for safety reasons to allow the accumulation of the residual dosage form in the stomach.

However, this alone was not sufficient and an additional design feature in these systems was that they released a fraction of the drug in a more absorbable immediate release form that contributed to baclofen levels only for the initial duration of the 24 hr dosing nevertheless it obtained 24 hrs desired plasma levels by combining the more absorbable form with the slow release form which is criticized in the prior art as being “poorly absorbable”.

Images